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Abstract
Background: In addition to its complement-regulating activity, CD55 is a ligand of the adhesion class G protein-coupled
receptor CD97; however, the relevance of this interaction has remained elusive. We previously showed that mice lacking a
functional CD97 gene have increased numbers of granulocytes.
Methodology/Results: Here, we demonstrate that CD55-deficient mice display a comparable phenotype with about two-fold
more circulating granulocytes in the blood stream, the marginated pool, and the spleen. This granulocytosis was independent of
increased complement activity. Augmented numbers of Gr-1-positive cells in cell cycle in the bone marrow indicated a higher
granulopoietic activity in mice lacking either CD55 or CD97. Concomitant with the increase in blood granulocyte numbers, Cd55-/-
mice challengedwith the respiratory pathogen Streptococcus pneumoniae developed less bacteremia and died later after infection.
Conclusions: Collectively, these data suggest that complement-independent interaction of CD55 with CD97 is functionally
relevant and involved in granulocyte homeostasis and host defense.
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Introduction
Decay-accelerating factor (CD55) is a GPI-anchored molecule
on leukocytes, erythrocytes, and serum-exposed stromal cells that
accelerates the decay of the complement convertases C3 and C5
[1,2]. The importance of CD55 for preventing endogenous cells
from unwanted complement activation is evident from the
phenotype of CD55-deficient mice that develop exaggerated
autoimmune reactions in a variety of spontaneous and induced
models [3–8]. Furthermore, studies in CD55-/- mice showed that
complement activation not only facilitates innate immune
responses but also adaptive immunity [9–13]. Next to the well-
established function as regulator of the complement cascade,
CD55 is engaged in complement-independent processes and is
hijacked by several viral and bacterial pathogens to promote cell
adhesion and invasion [14,15]. Furthermore, we demonstrated
previously that CD55 is a binding partner of CD97 [16].
CD97 is a member of the EGF-TM7 family of adhesion class G
protein-coupled receptors (GPCRs), abundantly expressed by
virtually all immune cells [17–22]. Like most adhesion GPCRs,
CD97 is a two-subunit molecule consisting of an extracellular a
subunit that is non-covalently associated with a seven-transmem-
brane (TM7) b subunit [19]. At the N-terminus, CD97 possesses
tandemly arranged epidermal growth factor (EGF)-like domains of
which the first two interact with the N-terminal short consensus
repeats (SCR) of CD55 [23–25]. We recently found that CD97
expression levels on leukocytes are increased significantly and
reversibly in CD55 knockout mice, proving for the first time that
both molecules interact in vivo (manuscript in preparation). The
physiological consequences of the interaction between CD55 and
CD97 are still poorly understood. A notable finding in mice lacking
a functional CD97 gene was a raise in granulocyte numbers in the
periphery [26,27]. To explore whether this phenotype was due to
abrogation of the CD97-CD55 interaction, we studied the size and
functionality of the granulocyte compartments in CD55-deficient
mice. We found that CD55-deficient mice, like mice that lack
CD97, had increased levels of circulating granulocytes, which was
due to a higher granulopoietic activity in the bone marrow.
Furthermore, mice lacking CD55 were better protected against S.
pneumoniae-induced pneumonia. Together, our data indicate a role
for the interaction between CD55 and the adhesion GPCR CD97
in granulocyte homeostasis and host defense.
Materials and Methods
Mice
Mice deficient for CD55 (Cd55-/-, synonym: Daf1-/-) and CD97
(Cd97-/-) have been generated previously by us [27,28]. Mice
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lacking the receptors for C3a (C3ar1-/-) and C5a (C5ar1-/-) were
kind gifts of Prof. Graig Gerard (Harvard Medical School, Boston,
MA, USA) [29,30]. Compound mice were created by crossing
Cd55-/- mice with Cd97-/-, C3ar1-/-, and C5ar1-/- mice [11]. All
genetically modified mice were back-crossed to C57BL/6 for at
least eight generations. C57BL/6 wild-type mice were littermates
or were purchased from Charles River (Maastricht, The Nether-
lands). Congenic mice expressed Cd45.1 in the B6.SJL strain. All
mice used in this study were matched for age and sex and kept
under specific pathogen-free conditions.
The research described in this paper complied with the ethics
guidelines of the University of Amsterdam. All experiments were
approved by the Animal Care and Use Committee of the
University of Amsterdam under the following project numbers:
DSK35, DSK1100, DSK100738, DSK101686, and DIX100121.
Flow cytometry
Peripheral blood was collected in heparin by heart puncture.
Single cell suspensions of spleen were made by mashing the organs
through a 70-mm cell strainer. Bone marrow cells were harvested
from dissected femurs by flushing the bone marrow plug with
phosphate buffered saline PBS/0.5% bovine serum albumin
(BSA). Erythrocytes were lysed with a buffer containing 155 mM
NH4Cl, 10 mM KHCO3, and 1 mM EDTA in all these cell
preparations. 25 ml whole blood or 56105 splenocytes or bone
marrow cells were used per staining. Nonspecific binding of
monoclonal antibodies (mAbs) was blocked by adding 10% normal
mouse serum and 1.25 mg/ml anti-CD16/32 (clone 2.4G2; BD
Biosciences). Staining was performed with appropriately diluted
PE-conjugated anti-Gr-1 or anti-Ly6G and APC-conjugated anti-
CD11b (eBioscience, San Diego, CA, USA) in PBS containing
0.5% BSA for 30 min at 4uC. Flow cytometric analysis was
performed using a FACSCalibur or FACSCanto (BD Biosciences)
and the FlowJo software package (Tree Star, Ashland, OR, USA).
Absolute numbers were calculated on basis of total cell counts
measured on a CASY cell counter (Scha¨rfe, Reutlingen, Germany)
or FACSCalibur multiplied by the percentage of cells positive for a
specific marker, as measured by flow cytometry.
Demargination assay
Heparin blood samples were taken 2 days before and 30 min
after an intraperitoneal (i.p.) injection of 0.25 mg/kg epinephrine
[31] via vena saphena and heart puncture, respectively. Erythro-
cytes were lysed as described above and PBL were analyzed for
cellular composition by flow cytometry.
Assessment of apoptosis
Peripheral blood lymphocytes (PBL) were cultured in the
presence of RPMI with 10% fetal calf serum for 20 h at 37uC.
At 0 and 20 h, the amount of viable granulocytes was analyzed by
flow cytometry with the use of Mitotracker Orange (Invitrogen,
Carlsbad, CA, USA) and antibodies against CD11b and Ly6G
(eBioscience).
BrdU labeling
Bromodeoxyuridine (BrdU; Sigma-Aldrich, St. Louis, MO,
USA) was given by a single i.p. injection at a dose of 5 mg/mouse
[32]. Blood was obtained daily via vena saphena puncture to
monitor BrdU+Ly6G+ cells. Erythrocytes were lysed as described
above, and cells were stained with PE-conjugated Ly6G antibody.
After fixation steps with 220uC-cold 70% ethanol (30 min on ice)
and paraformaldehyde (minimum 3 h at 4uC), cells were treated
with DNAse (Sigma-Aldrich) (10 min at room temperature
followed by 30 min on ice) and stained intracellularly with a
FITC-conjugated BrdU antibody (eBioscience). Analysis was
performed by flow cytometry. Absolute numbers of BrdU-positive
granulocytes were calculated on the basis of granulocyte numbers
in blood and the percentage of BrdU-positive granulocytes within
the Ly6G-positive gate.
Determination of cell cycle status
26106 bone marrow cells, prepared without lysing erythrocytes,
were stained for Gr-1 and subsequently fixated in 220uC-cold
70% ethanol for 30 min on ice. At least 5 min before analysis by
flow cytometry, 10 mg/ml propidium iodide (PI; Sigma-Aldrich)
was added to the cells. Doublets and debris were excluded from
analysis by setting an appropriate FSC-SSC gate, and Gr-1+ cells
with. 2N DNA content, measured with PI, were considered to be
in G2/S phase [33].
Pneumococcal pneumonia
Pneumonia was induced in wild-type and Cd55-/- mice as
described previously [27]. Briefly, S. pneumoniae serotype 3 was
obtained from American Type Culture Collection (ATCC 6303;
Rockville, MD, USA). Pneumococci were grown for 6 h to mid-
logarithmic phase at 37uC in 5% CO2 using Todd-Hewitt broth
(Difco, Detroit, MI, USA), harvested by centrifugation at 1500 x g
for 15 min, and washed twice in sterile isotonic saline. Bacteria
were then resuspended in sterile isotonic saline at a concentration
of approximately 96104 colony-forming units (CFU)/50 ml as
determined by plating serial 10-fold dilutions on sheep blood agar
plates. Mice were lightly anesthetized and inoculated intranasally
(i.n.) with 50 ml.
At 24 h and 48 h after inoculation, mice were anesthetized and
sacrificed by heart puncture. Blood was collected in EDTA-
containing tubes, and lungs and spleen were harvested in sterile
saline. One lung lobe was fixed in 10% formalin and embedded in
paraffin. 4-mm sections were stained with hematoxylin and eosin
(H&E) and analyzed by a pathologist who was blinded for groups.
The other lung lobe and spleen were homogenized at 4uC in four
volumes of sterile saline using a tissue homogenizer (BioSpec
Products, Bartlesville, OK, USA). CFU were determined from
serial dilutions of lung and spleen homogenates and blood, plated
on blood agar plates and incubated at 37uC at 5% CO2 for 16 h
before colonies were counted. For cytokine and chemokine
measurements, lung homogenates were diluted 1:2 in lysis buffer
containing 300 mM NaCl, 30 mM Tris, 2 mM MgCl2, 2 mM
CaCl2, 1% Triton X-100, and pepstatin A, leupeptin, and
aprotinin (all 20 ng/ml; pH 7.4) and incubated at 4uC for 30
min. Homogenates were centrifuged at 1500 x g at 4uC for
15 min, and supernatants were stored at -20uC until assays were
performed. Cytokines (TNF, IL-1b) and chemokines (KC,
macrophage-inflammatory protein-2 (MIP-2)) were measured
using specific ELISA (R&D Systems, Minneapolis, MN, USA)
according to the manufacturer’s instructions. Myeloperoxidase
levels were quantified by MPO ELISA (HBt, Uden, The
Netherlands) according to the manufacturer’s protocol. In a
separate group of mice, survival was monitored.
Thioglycollate-induced peritonitis
Sterile peritonitis was induced by i.p. injection of 1 ml 4% aged
thioglycollate broth (Sigma-Aldrich). After 4 h, peritoneal lavages
were performed with 4 ml ice-cold 2 mM EDTA in PBS.
Peritoneal cells were counted on a CASY cell counter (Scha¨rfe,
Reutlingen, Germany) and analyzed for cellular composition by
flow cytometry.
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Statistical analysis
Differences between groups were calculated by unpaired t-test
or Mann-Whitney U test. For comparison of multiple groups one-
way ANOVA with Bonferroni’s multiple comparison test was
used. The effect of lack of CD55 on the number of BrdU-positive
granulocytes in circulation was assessed by calculating the
cumulative area under the curve, followed by the Wilcoxon
rank-sum test. For survival analysis, Kaplan-Meier analysis
followed by log rank test was performed. A two-tailed p value of
less than 0.05 was considered to represent a significant difference.
Results
Mice lacking CD55 have increased levels of circulating
granulocytes
CD97-deficient mice display a mild granulocytosis [26,27].
When we analyzed the hematopoietic compartment in Cd55-/-
mice, we found a comparable phenotype (Figure 1A+B). The
percentage and absolute number of CD11b+Ly6G+ granulocytes
was increased in the blood of about half and in the spleen of almost
all mice lacking CD55. In bone marrow, the increase in mature
granulocyte (CD11b+Gr-1high) numbers was less pronounced.
There were no differences in the amount of CD11b+Gr-1int cells,
which according to Ueda et al. [33] represent immature precursors
of granulocytes. Next to granulocytes, we did observe an increased
amount of monocytes in the blood of mice lacking CD55; yet, this
was not consistent and not clearly found in spleens of these mice.
The striking similarity between Cd55-/- and Cd97-/- mice with
respect to granulocyte numbers led us to compare them side-by-
side in combination with compound mice, lacking both genes. We
found a comparable increase in the percentage and absolute
number of granulocytes in Cd55-/- and Cd97-/- mice that was not
further increased in double knockout Cd55-/-Cd97-/- mice
(Figure 2A).
Increased local production of C3a and C5a and subsequently
increased C3a and C5a receptor signaling in Cd55-/- mice has
been shown to be involved in T-cell survival [11]. Furthermore,
C5a has been demonstrated to protect granulocytes from apoptosis
[34]. In order to test whether increased C3a and C5a receptor
signaling was involved in the displayed granulocytosis in Cd55-/-
mice, we assessed circulating granulocyte numbers in
Cd55-/-C3ar-/-C5ar-/- compound mice. Figure 2B shows that
CD55-deficient mice still displayed granulocytosis when C3a and
C5a receptor signaling was abrogated, indicating that increased
granulocyte numbers in the Cd55-/- mice did not result from
enhanced complement receptor activation.
Expanded granulopoietic activity in CD55-deficient and
CD97-deficient mice
In order to obtain insight into the mechanism behind the
observed granulocytosis, we started out by exploring the total
population of mature peripheral granulocytes. These can exist as
Figure 1. Lack of CD55 causes a mild granulocytosis. Immune cells obtained from bone marrow, blood, and spleen of wild-type and Cd55-/-
mice were incubated with antibodies against Ly6G (or Gr-1) and CD11b and analyzed by flow cytometry. (A) Representative dot plots showing Gr-1
against CD11b expression on bone marrow-derived cells and Ly6G against CD11b expression on PBL and splenocytes of wild-type and Cd55-/- mice.
(B) Percentages (upper panels) and total numbers (lower panels) of mature granulocytes in one femur (CD11b+Gr-1high), 1 ml blood (CD11b+Ly6G+),
or in total spleen (CD11b+Ly6G+) of wild-type and Cd55-/- mice. Circles represent individual mice and horizontal lines indicate the mean of the
percentage or absolute number of granulocytes per group (n = 7-35). *, p,0.05 and ***, p,0.0005
doi:10.1371/journal.pone.0024431.g001
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freely circulating cells as well as reversibly adhered cells to the
vascular endothelium [35]. The latter so called marginated cells
can be released into circulation by epinephrine injection, making
them accessible for blood sampling [31]. We found that in
response to i.p. application of epinephrine, granulocyte numbers
in wild-type mice increased almost 3-fold from 4.66105/ml to
13.16105/ml. Cd55-/- mice exhibited a similar increase
(10.06105/ml to 23.86105/ml), resulting in granulocyte counts
that again were significantly higher compared to wild-type mice
(Figure 3A). The normal epinephrine response seen in mice
lacking CD55 suggested that the displayed granulocytosis in these
mice is not caused by a defect in margination of granulocytes.
Pre-mature mobilization from bone marrow would be another
possibility to explain the increased number of granulocytes in
circulation [35]. However, when we analyzed blood smears of
Cd55-/- mice, we found that almost all granulocytes had a mature,
segmented phenotype, and no differences were found between
Cd55-/- granulocytes compared to wild-type cells (data not shown).
We next tested the possibility of an increased survival of
granulocytes in the periphery in Cd55-/- mice. We started with the
assessment of granulocyte apoptosis ex vivo by culturing PBL for 20
h, followed by measuring survival rates using Mitotracker. Both
wild-type and Cd55-/- granulocytes displayed a considerable
amount of apoptosis, which was not different between the two
mouse strains (Figure 3B). Granulocytes are short-lived cells with a
half-life in circulation of less than one day under normal
conditions [35]; and although Cd55-/- granulocytes did not display
an altered apoptosis rate ex vivo, it could be possible that they are
not cleared from circulation as efficient as in wild-type mice. To
assess this possibility, we studied the life span of circulating
granulocytes in vivo. To this end, dividing granulocytes in the bone
marrow were pulse-labeled by a single i.p. injection of BrdU [32],
and their kinetics in circulation was determined by measuring
Ly6G-positive cells that had incorporated BrdU. We found a
comparable transit time for BrdU-positive granulocytes to appear
in circulation in wild-type and Cd55-/- mice with a peak
percentage at 72 h (Figure 3C, left panel). Also the disappearance
of labeled cells from blood was not changed in Cd55-/- mice
(Figure 3C, left panel). However, the numbers of BrdU-positive
granulocytes in circulation in Cd55-/- mice were significantly
Figure 2. Increased granulocyte numbers in Cd55-/- mice does not result from enhanced complement activity. Immune cells obtained
from blood of wild-type and knockout mice were incubated with antibodies against Ly6G and CD11b and analyzed by flow cytometry. Percentages
(upper panels) and total numbers (lower panels) of granulocytes in blood of (A) wild-type, Cd55-/-, Cd97-/-, and Cd55-/-Cd97-/- mice and (B) wild-type,
Cd55-/-, and Cd55-/-C3ar-/-C5ar-/- mice. Circles represent individual mice, and horizontal lines indicate the mean of the percentage or absolute number
of granulocytes per group (n = 7-38). *, p,0.05; **, p,0.005; ***, p,0.0005
doi:10.1371/journal.pone.0024431.g002
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higher throughout the duration of the experiment (Figure 3C,
right panel). We concluded that despite a normal life span in
circulation, the amount of granulocytes produced and released
from the bone marrow was significantly increased in Cd55-/- mice.
Interestingly, Wang et al. showed that CD97-deficient mice had
no altered apoptotic rate but they observed an increased response
to daily G-CSF injections, also suggesting greater granulopoietic
production [26].
To corroborate the hypothesis that both CD55-deficient and
CD97-deficient mice had an increased granulopoietic activity, we
studied the proliferative activity of Gr-1-positive cells in the bone
marrow by measuring their DNA content [33]. Cd55-/- mice
displayed an increased percentage of cells that were in S or G2/M
phase of the cell cycle as compared to wild-type mice (Figure 3D).
Of note, side-by-side comparison revealed a similar increase in the
percentage of dividing Gr-1-positive cells in the bone marrow in
Cd97-/- mice (Figure 3D). Together, these data suggest that the
granulocytosis in the periphery of mice lacking either CD55 or
CD97 is caused by an increased granulopoiesis.
Augmented protection against pneumococcal
pneumonia in CD55-deficient mice
To determine possible consequences of CD55 deficiency for
anti-bacterial host defense, mice were inoculated with a lethal dose
of S. pneumonia (96104 CFU) and monitored over time. While wild-
type mice all died at day 3 after infection (median survival time =
64.5 h), Cd55-/- lived up till day 5 after infection (median survival
time = 111.3 h) (Figure 4A). To obtain insight in how Cd55-/-
mice were protected against lethality during pneumococcal
pneumonia, we examined bacterial loads in the lungs and blood
24 h and 48 h after infection (Figure 4B and C). Most notably, at
these time points, Cd55-/- mice had significantly lower bacterial
loads in blood. Of the wild-type animals, 75% had positive blood
cultures, whereas only 37.5% of the Cd55-/- blood cultures were
positive 24 h after infection. At 48 h, all wild-type mice showed
positive blood cultures while in the Cd55-/- group, only 62.5%
showed bacterial outgrowth (Figure 4B). Furthermore, at 48 h,
Cd55-/- mice had slightly lower bacterial loads in their lungs
compared to wild-types mice (Figure 4C).
Histopathological examination of lung sections showed no
differences in lung inflammation between wild-type and Cd55-/-
animals at 24 h (data not shown) and 48 h after infection
(Figure 4D). Also, the local concentration of the pro-inflammatory
cytokines TNFa and IL-1b and the chemokines KC and MIP-2
was not different between wild-type and Cd55-/- mice at 24 h and
48 h after infection (data not shown). Finally, the amount of
phagocytic cells present in infected lungs increased over time, but
no difference was found between wild-type and Cd55-/- mice as
Figure 3. Cd55-/- and Cd97-/- mice have an increased granulopoietic capacity. (A) Blood was collected from wild-type and Cd55-/- mice two
days before and 30 min after i.p. injection of 0.25 mg/kg epinephrine, and the number of granulocytes per ml blood was measured by flow
cytometry. Bars and error bars represent the mean and SD of the number of granulocytes (n = 3-5). (B) PBL from wild-type and Cd55-/- mice, cultured
overnight at 37uC, were stained with Mitotracker and analyzed by flow cytometry. Shown is the mean and SD of the percentage of Mitotracker-
negative apoptotic granulocytes (n = 4). (C) Blood was collected from wild-type and Cd55-/- mice via vena saphena puncture at the indicated time
points after a single i.p. injection of 5 mg BrdU. PBL were stained for Ly6G and BrdU and analyzed by flow cytometry (left panel). The mean and SD of
the percentages (left panel) and absolute numbers (right panel) of BrdU-positive granulocytes are depicted (n = 3–5). (D) Wild-type, Cd55-/-, and
Cd97-/- bone marrow cells were harvested and analyzed by flow cytometry for dividing cells. To the left, representative histograms showing the
percentage of granulocytes with . 2N DNA content in wild-type, Cd55-/-, and Cd97-/- mice are provided. To the right, the mean and SD of the
percentage of granulocytes with . 2N DNA content is depicted (n = 3–4). One of two comparable experiments is shown. *, p,0.05 and **, p,0.005
doi:10.1371/journal.pone.0024431.g003
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determined by the amount of myeloperoxidase present in lung
homogenates (Figure 4E). To further substantiate the point that
migration of Cd55-/- granulocytes to sites of inflammation is
normal, we induced sterile peritonitis with 4% thioglycollate in
wild-type and Cd55-/- mice. Also in this sterile model of
inflammation, we saw comparable accumulation of granulocytes
in wild-type and Cd55-/- mice (absolute number of granulocytes in
peritoneal exudate = 17.4610662.0 and 17.0610664.0, respec-
tively).
To test the possibility that Cd55-/- granulocytes were function-
ally more competent, we examined the production of reactive
oxygen species (ROS) upon various stimuli. PMA, zymosan,
serum-treated zymosan, or PAF/fMLP was used to stimulate
granulocytes derived from bone marrow of wild-type and Cd55-/-
mice. No differences were found with respect to the amount of
ROS produced, the time to produce it, or the percentage of
granulocytes that produced ROS in response to stimulation (data
not shown). We concluded that a better protection from
bacteremia due to increased granulocyte numbers rather than
qualitative improvement of immunity in the lungs likely reduced
lethality from S. pneumonia in Cd55-/- mice.
Discussion
We here provide evidence for a novel role of the complement
control protein CD55 in granulocyte homeostasis and anti-
bacterial host defense. CD55-deficient mice display increased
numbers of circulating granulocytes. On average, we found twice
as many granulocytes in the blood stream, the marginated pool,
and the spleen of Cd55-/- compared to wild-type mice. This mild
granulocytosis clearly differs from the marked changes in mice that
lack leukocyte adhesion molecules [35]. A comparable phenotype
has recently been reported in two independently generated CD97-
deficient mice [26,27]. The Kelly laboratory and we found that
mice lacking CD97 have about two-fold increased granulocyte
numbers in blood and spleen in the steady state. This phenotype
was not the result of enhanced bone marrow emigration to the
blood neither of reduced clearance of circulating cells. Cd97-/-
mice showed a greater response to daily G-CSF treatment, which
induces granulopoiesis in the bone marrow [26]. In line with this
observation, we here demonstrate increased numbers of Gr-1-
positive cells in cell cycle in the bone marrow of both CD55-
deficient mice and CD97-deficient mice, indicating a higher
granulopoietic activity in both strains.
Several pieces of evidence suggest that the role of CD55 in
granulocyte homeostasis relates to its interaction with CD97.
Firstly, the granulocytosis in both mouse strains is highly
comparable and not further accelerated in compound mice.
Secondly, mice lacking CD55 and the receptors for C3a and C5a
had granulocyte numbers comparable to CD55-deficient mice,
excluding a causal link with exaggerated complement receptor
activation in the absence of CD55. Thirdly, as discussed above,
both Cd55-/- and Cd97-/- mice displayed enhanced granulopoietic
activity. These data suggest that both molecules through their
interaction in bone marrow jointly affect granulocyte homeostasis.
How this occurs at the molecular level is currently unknown. Both
CD55 and CD97 are differentially expressed during the
development of hematopoietic progenitor cells [36,37]; moreover,
CD55 is present on stromal cells and can be deposited in the
extracellular matrix [1,38]. Thus, the interaction between CD55
and CD97 can be involved in various contacts between
hematopoietic progenitors and stromal cells. This concept would
fit with recent data suggesting that adhesion GPCRs by facilitating
cell and matrix contacts contribute to the proper positioning of
developing cells in a variety of organ systems [39–41].
Granulocytes are crucially involved in anti-bacterial host
defense. To test whether increased granulocyte number exaggerate
the innate response in CD55-deficient mice, we applied an acute
model of pneumococcal pneumonia. In response to a lethal dose of
S. pneumonia, Cd55-/- mice displayed a better clearance of bacteria
from blood and lung correlating with an extended survival
compared to wild-type mice. Increased complement activation in
the absence of CD55 may ameliorate this exaggerated response
and might explain why a similar protective effect was not found
previously by us in Cd97-/- mice [27]. However, Kelly and
colleagues reported that Cd97-/- mice are more resistant to Listeria
monocytogenes, correlated with a more robust accumulation of
granulocytes in the blood and the liver of infected mice [26].
Our study strengthens the view that the interaction with CD97
is a physiologically relevant, complement-independent activity of
CD55. Further support for the idea was obtained in a recent study,
showing a comparable level of protection from experimental
arthritis in Cd55-/- and Cd97-/- mice, which might relate to a role
of both molecules in the retention of leukocytes in the inflamed
synovium [42] Of note, CD55 is the first binding partner that is
linked functionally to an adhesion GPCR in vivo [43].
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